Tanzania has made genuine progress in transplant medicine over the last decade. Benjamin Mkapa Hospital (BMH) in Dodoma is now the only hospital in East and Central Africa performing bone marrow transplants (BMT) for children with sickle cell disease, and it has been recognised by the East African Community as a regional Centre of Excellence for the procedure. That’s a real achievement, and it matters for the region.
But for a Tanzanian family facing an actual diagnosis today — leukemia, thalassemia, aplastic anemia, or a sickle cell case that needs a transplant now rather than in a few years — the honest question is: where should your family go? This guide compares the two options directly, on the factors that actually decide outcomes: transplant volume, donor access, technology, specialist depth, and total cost. Let us look why bone marrow transplant in India is still a better option.
Quick Comparison Table
| Factor | Benjamin Mkapa Hospital (Tanzania) | Indraprastha Apollo Hospital, Delhi |
| BMT programme age | Since 2018; first sickle cell BMT success in 2023 | Multi-decade programme across 4+ dedicated transplant centres |
| Annual transplant volume | Small, growing cohort (currently ~50 patients on waiting list) | Hundreds of transplants per year across the network |
| Transplant types offered | Primarily allogeneic BMT for sickle cell disease in children | Autologous, allogeneic (sibling & unrelated donor), haploidentical, cord blood, full pediatric programme |
| Donor registry access | Limited to related/regional donor matching | Access to large national and international unrelated donor registries |
| Estimated cost | ~Tsh 75 million (~$29,000–$30,000) | $15,000–$33,000 depending on transplant type |
| Wait time | Currently constrained — 50 children on waiting list for limited capacity | Faster scheduling once case is accepted, due to higher bed and specialist capacity |
| International patient support | Domestic-focused; not yet built for cross-border case management | Dedicated international patient desks, visa support, telemedicine follow-up |
Bone Marrow Transplant India vs Tanzania-Comparison
Track Record and Transplant Volume
This is the single biggest factor in BMT outcomes, and it isn’t close.
BMH performed Tanzania’s first successful sickle cell BMT in 2023 and has since completed transplants on 30 children, with 12 discharged and back in school — a genuinely encouraging start for a programme still in its early years.
Indraprastha Apollo Hospital, Delhi , by comparison, operates one of the largest BMT networks in Asia, with dedicated transplant units in Delhi, Chennai, Hyderabad, and Mumbai, performing autologous, allogeneic, haploidentical, cord blood, and pediatric transplants at volumes exceeding hundreds of procedures per year.
In transplant medicine, hospitals performing 100+ procedures annually consistently show better outcomes than lower-volume centres — because the surgical team, the ICU staff, the infection-control protocols, and the post-transplant care pathway are all more practiced.
What this means for a patient: a young programme can still deliver a successful transplant, but a high-volume centre has seen far more of the complications, rare reactions, and edge cases that determine whether a transplant succeeds — and has systems built specifically to manage them.
Donor Matching and Transplant Types
BMH’s programme is currently focused on allogeneic transplants for sickle cell disease in children, generally relying on related or regional donor matches. This is an important and appropriate starting point, but it does not yet include the full spectrum of transplant options.
Apollo offers the complete range of Bone marrow transplant in India: autologous transplants (using the patient’s own cells), matched sibling donor transplants, matched unrelated donor (MUD) transplants drawing on large national and international donor registries, haploidentical transplants (using a half-matched family donor — critical when no full match exists), and cord blood transplants. For many blood cancers and disorders, especially in patients without a sibling match, access to a haploidentical or MUD programme is what makes a cure possible at all.
What this means for a patient: if a sibling match isn’t available — which is the case for roughly two-thirds of patients — a centre with a mature unrelated-donor and haploidentical programme has a real, practical advantage.
Facilities and Technology
BMT requires more than a skilled surgeon. It requires HEPA-filtered positive-pressure isolation rooms, a dedicated transplant ICU, an in-house blood bank capable of rapid component support, and a multidisciplinary team of hematologists, infectious disease specialists, and transplant nurses working in constant coordination for weeks at a stretch.
BMH has invested heavily in infrastructure — the hospital now runs 20 specialised and 18 super-specialised departments and is currently expanding its BMT unit from three isolation rooms to six. This expansion is a genuine sign of progress, but it also confirms the programme is still scaling up its core infrastructure.
Apollo’s transplant centres already operate at this scale, with established isolation units, dedicated transplant ICUs, and infrastructure that has supported hundreds of pediatric and bone marrow transplants in India, including complex pediatric and haploidentical cases.
Doctors and Specialists
To be direct about something families often ask: BMH’s hematology team, including specialists like Dr Stella Malangahe, has done credible work and that deserves genuine respect. The limitation isn’t skill — its depth of bench.
Apollo’s BMT teams include doctors who have individually overseen large volumes of pediatric and adult transplants across thalassemia, sickle cell disease, leukemia, and primary immunodeficiency disorders — specialists whose case experience runs into the thousands collectively across the network, working alongside infectious disease physicians, transplant nutritionists, and psychosocial support teams built specifically around long BMT admissions
5. Cost — the Real Numbers
Bone marrow transplant cost in India and Tanzania needs real comparison, not marketing.
BMH: A Bone marrow transplant cost in Tanzania is approximately Tsh 75 million (roughly $29,000–$30,000) locally, government-subsidised in many cases through the hospital’s transplant fund.
Apollo (India): Autologous BMT cost $15,000–$22,000; allogeneic BMT with a matched sibling donor cost roughly $25,000–$33,000. Unrelated donor transplants cost more once international registry search and cell procurement are factored in.
On paper, the ranges overlap. But two things change the real-world calculation:
- Wait time has a cost too. BMH currently has around 50 children waiting for limited transplant slots. For a progressing blood cancer or a worsening sickle cell case, months on a waiting list is not a neutral cost — delay can change eligibility and outcomes.
- Total cost of care, not just the sticker price. A cheaper transplant with a longer wait, a less mature unrelated-donor programme, or a higher complication rate can end up costing more in the long run — in additional treatment, extended hospital stays, or the need for a second transplant.
Why India — and Apollo Specifically — Comes Out Ahead
Weighing all five factors together:
- Volume and experience: Bone marrow transplant doctors in India at Apollo have handled a far larger and more varied caseload than any current East African programme.Full donor-matching spectrum: access to haploidentical and unrelated-donor programmes matters enormously when no sibling match exists — which is the majority of cases.
Mature infrastructure: isolation units, transplant ICUs, and multidisciplinary teams that are already operating at scale, not still being built out.
Faster access to treatment: no multi-month waiting list for a limited number of slots.
Built for cross-border patients: dedicated international patient coordination, e-Medical Visa support, and telemedicine follow-up once the patient returns home — infrastructure Tanzania’s domestic programme isn’t yet designed around.
None of this takes away from what BMH has achieved — it is a real and important development for Tanzania and the wider East African region, and it will likely close this gap over the coming years as its programme matures. But for a family making a decision today, with a specific diagnosis and a specific timeline, India — and Apollo Hospitals in particular — currently offers the deeper bench, the broader donor access, and the faster path to treatment.
Frequently Asked Questions
Is a bone marrow transplant in India more expensive than in Tanzania?
Not necessarily. Autologous BMT in India can cost less than a transplant at BMH once currency conversion is applied, though matched sibling allogeneic transplants are roughly comparable in price. The bigger cost difference usually comes from wait time and the risk of needing a second procedure, not the headline price.
Do Tanzanian patients need a visa to get a bone marrow transplant in India?
Yes. Tanzanian patients apply for an e-Medical Visa, typically processed within 3–5 business days, valid for stays up to 60 days and extendable to 6 months. An accompanying family member travels on a separate e-Medical Attendant Visa.
How long does a patient need to stay in India for a bone marrow transplant?
Plan for a minimum of 3–4 months for an allogeneic transplant, covering treatment and initial recovery monitoring, since patients generally need to remain near the hospital for 60–100 days post-transplant.
Can Tanzanian patients get a bone marrow transplant without a sibling donor match?
Yes — this is one of the main reasons families choose Apollo. Its haploidentical and matched-unrelated-donor programmes allow bone marrow transplant in India to proceed even when no full sibling match is available, an option not yet consistently offered by Tanzania’s domestic programme.
Is Benjamin Mkapa Hospital a bad option for bone marrow transplant?
No — BMH’s programme is a genuine and valuable development for Tanzania, with real successful outcomes in sickle cell patients. It simply has less volume, a narrower donor-matching range, and a current waiting list, which is why many families with urgent or complex cases still choose to travel to India.
Contact Cross Border Care Today
If you are looking for immediate assistance for a bone marrow transplant in India, contact Dr Nadeem Khan from Cross Border Care today.
July 20, 2026
